President and CEO
Chief Medical Officer
Co-founder & Manager
Advisor & Manager
A key factor limiting the success of immuno-oncology therapy and adoptive cell therapy is the relatively low number of tumor specific T cells that physically enter a solid tumor. Tumors secrete agents that suppress the immune response and can actively alter their cell surface to prevent specific T cells from binding them and killing them. 7HP compounds are designed to overcome the ability of a tumor to evade the immune response by imparting on tumor specific T cells the capability to localize to, and efficiently kill, tumor cells.
Cord blood stem cell transplant is potentially curative for a variety of hematologic cancers and genetic diseases. However, the low number of stem cells in cord blood preparations limits their use primarily to pediatric patients, and can result in an increased risk of opportunistic infections, increased hospital costs, and high graft failure rates. 7HP compounds are designed to act as “cellular glue,” promoting cord blood stem cell adhesion and engraftment into the bone marrow resulting in improved patient outcomes.
7 Hills is managed by an experienced group of pharmaceutical executives with the requisite expertise to take the Company from molecule to market—the team has successfully developed and secured FDA approval for five New Drug Products.
7 Hills Pharma LLC is an immuno-oncology company developing drugs to treat drug resistant cancers. In spite of the unprecedented cure rates in rare cancers, the promise of immunotherapy and cell therapy is yet to be realized for solid tumors such as lung, colon, and other cancers. 7 Hills is developing cost-effective technologies that modulate the immune system to increase the effectiveness of immune checkpoint blockade, adoptive cell therapy, and cord blood transplant to treat solid tumors and orphan genetic diseases.